๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia

โœ Scribed by Nirmala Rajaram; Revati J. Tatake; Suresh H. Advani; Sanjeev L. Naik; Sudha G. Gangal


Publisher
Springer-Verlag
Year
1990
Tongue
English
Weight
547 KB
Volume
31
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Lymphokine-activated killer cells, natur
โœ Bice Perussia ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 965 KB

In the past year, natural killer cells have been the subject of much active investigation. The analysis of the effect of cytokines on the generation, proliferation and function of natural killer cells, and the definition of the lymphokines that they produce, have been particularly important areas of

Lymphokine-activated killer cell and nat
โœ Thomas V. Kantor; Theresa L. Whiteside; Diana Friberg; Robert B. Buckingham; Tho ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 499 KB ๐Ÿ‘ 2 views

Objective. To determine the ability of T lymphocytes and natural killer (NK) cells from patients with systemic sclerosis (SSc) to respond to cytokines and to generate immune effector cells. Methods. The numbers and percentages of peripheral blood T and NK cells were examined by 2-color flow cytometr

Defective function of lymphokine-activat
โœ Toshiji Saibara; Saburo Onishi; Hiroshi Sakaeda; Yasutake Yamamoto ๐Ÿ“‚ Article ๐Ÿ“… 1989 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 608 KB

Lymphokine-activated killer activity and natural killer activity in hepatocellular carcinoma patients were d. Maximum lymphokine-activated killer activity was induced at 3 to 6 days of incubation, and lymphokine-activated killer activity tended to increase in a manner dose dependent of recombinant i

Apheresis techniques in lymphokine-activ
โœ Irena Sniecinski; Kim Sentinella; Kim Margolin; Bonnie Mills ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 385 KB

Adoptive transfer of autologous lymphokine-activated killer cells (LAK) in conjunction with recombinant interleukin-2 (rIL-2) has been reported to produce significant regression in metastatic disease in patients with advanced cancer. In an effort to confirm the results reported by the Surgery Branch